Barriers and facilitators to nationwide implementation of the malaria vaccine in Ghana.
Ghana
Malaria
RTS
S/AS01E malaria vaccine
children under 5 years
force field analysis
implementation programme
pilot
qualitative research
Journal
Health policy and planning
ISSN: 1460-2237
Titre abrégé: Health Policy Plan
Pays: England
ID NLM: 8610614
Informations de publication
Date de publication:
06 Jan 2023
06 Jan 2023
Historique:
received:
04
11
2021
revised:
05
08
2022
accepted:
09
09
2022
pubmed:
10
9
2022
medline:
11
1
2023
entrez:
9
9
2022
Statut:
ppublish
Résumé
Interventions such as antimalarial drugs, bed nets and insecticides have helped curb the burden of malaria in the past decade, yet malaria remains a leading cause of morbidity and mortality in children below the age of 5 years. In 2019, Ghana, Malawi and Kenya in sub-Saharan Africa (countries with moderate to high transmission areas of malaria and deaths) started piloting the RTS,S/AS01E malaria vaccine in selected regions. Using qualitative methods, this study examined the main factors (forces) that will influence or hinder the nationwide implementation of the malaria vaccine, if approved, in Ghana. We conducted in-depth interviews with 12 key individuals (national, research/academia and programme implementing partners) in the public health sector in Ghana from October 2018 to February 2019. Results were analysed using Kurt Lewin's force field analysis to understand how organizations interact with their external environment in the delivery of health policies such as the implementation of the malaria vaccine. We found that the disease burden of malaria deaths in Ghana, the efficacy of the vaccine, stakeholder involvement and evidence for the feasibility of vaccine delivery generated by the consortium of researchers (body of researchers) that can track the implementation were the driving forces to scale up the vaccine into a routine health system. On the other hand, the needed logistics, funding, administration of the four-dose vaccine and follow-up were identified as potential barriers. The most influential force collectively highlighted by the respondents was the disease burden, and the most influential barrier was the logistics of delivering the vaccine. Our findings provide decision makers with key barriers and facilitators to guide policy and decision-making for malaria control in Ghana and other similar settings in low- and middle-income countries.
Identifiants
pubmed: 36083007
pii: 6694852
doi: 10.1093/heapol/czac077
pmc: PMC9825729
doi:
Substances chimiques
Malaria Vaccines
0
Antimalarials
0
Types de publication
Journal Article
Langues
eng
Pagination
28-37Informations de copyright
© The Author(s) 2022. Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine.
Références
Malar J. 2019 Apr 8;18(1):122
pubmed: 30961603
Malar J. 2017 Apr 26;16(1):177
pubmed: 28446198
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Hum Vaccin Immunother. 2013 Aug;9(8):1774-8
pubmed: 23733039
Nat Biotechnol. 2015 Oct;33(10):1015-6
pubmed: 26448075
BMC Public Health. 2020 Feb 19;20(1):254
pubmed: 32075630
Trials. 2019 May 31;20(1):316
pubmed: 31151473
Health Promot Pract. 2004 Jul;5(3):306-13
pubmed: 15228786
Pan Afr Med J. 2019 Dec 05;34:179
pubmed: 32153719
Front Public Health. 2021 Aug 06;9:709127
pubmed: 34422750
Lancet. 2016 Jan 23;387(10016):367-375
pubmed: 26549466
PLoS Med. 2021 Feb 16;18(2):e1003537
pubmed: 33591995
Glob Health Action. 2017;10(1):1381471
pubmed: 29035160
BMC Med. 2015 Jul 29;13:170
pubmed: 26219380
Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24486-24491
pubmed: 31740595
Hum Vaccin Immunother. 2020 Mar 3;16(3):480-489
pubmed: 31545128
Malar J. 2019 Mar 11;18(1):67
pubmed: 30871551
Cochrane Database Syst Rev. 2019 May 23;5:CD012688
pubmed: 31120132
PLoS Med. 2011 Oct;8(10):e1001107
pubmed: 22028630
J Nurs Manag. 2003 Jul;11(4):275-80
pubmed: 12801382
BMC Infect Dis. 2014 Aug 06;14:431
pubmed: 25100574
PLoS One. 2008 Jun 25;3(6):e2530
pubmed: 18575626
Int J Gen Med. 2013 Sep 11;6:757-64
pubmed: 24049454
Ghana Med J. 2019 Sep;53(3):252-253
pubmed: 31741498
BMC Pediatr. 2018 Oct 11;18(1):323
pubmed: 30309343
Lancet. 2019 Apr 27;393(10182):1685
pubmed: 31034365
PLoS Med. 2014 Jul 29;11(7):e1001685
pubmed: 25072396
Arch Public Health. 2017 Mar 13;75:10
pubmed: 28293422
J Infect Dis. 2021 Jan 4;223(1):7-9
pubmed: 32621744
BMC Public Health. 2020 Jun 12;20(1):910
pubmed: 32532234
AIMS Microbiol. 2021 Feb 08;7(1):96-113
pubmed: 33659771
Online J Issues Nurs. 2011 Aug 15;16(3):7
pubmed: 22324573
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
PLoS Med. 2020 Nov 30;17(11):e1003377
pubmed: 33253211
BMC Med. 2017 Jul 26;15(1):138
pubmed: 28743299